Articular cartilage damage, especially when it affects the knee joint, remains a major clinical problem due to the poor intrinsic ability for this tissue to repair itself. The major function of joint cartilage is to allow for smooth gliding of joint surfaces and to protect the surrounding bone from stress. This sort of movement is key for individuals who participate in sports such as skiing. In a wider context, though, knee cartilage damage can prevent people from running, exercising, or just moving as freely as theyd like. Articular cartilage allows the knee to absorb shock and loads up to 20 times the body weight.

There are many reasons why someone may experience articular knee cartilage damage. Regular wear and tear on the knee over time, involvement in high-stress activities, or accidents and injuries can all contribute to cartilage damage around the knee joint.

Osteoarthritis is a chronic degenerative disorder that ultimately leads to a gradual deterioration of knee joint cartilage. Osteoarthritis may also be the result of a prior injury to the knee joint such as a fracture, tendon damage, or ligament tears.

This may lead to joint instability, which can cause long-term damage to the articular cartilage. Arthritis can affect not only the cartilage but may also lead to damage of the bone beneath the cartilage, the synovial lining to the joint, ligaments, tendons, and muscles.

Adult stem cells are incredibly versatile in a medical sense. They have a potential to reliably differentiate into cartilage, bone, fat, or soft tissue. Because of this, the injection of progenitor cells, especially mesenchymal stem cells (special stem cells from adipose tissue or bone marrow), have been shown to be a better strategy to repair degenerative cartilage than implantation of differentiated cells such as articular cartilage.

In other words, when adult stem cells are injected into a knee with damaged cartilage, they can act to repair damaged tissue and build new cartilage.

Adult stem cells also display the ability to specifically address areas of inflammation and degeneration and to modify immune system activity, which can favorably influence the surrounding cartilage in areas of damage.

Encouragingly, results of pre-clinical and clinical trials have provided initial evidence of efficacy and safety in the therapeutic use of mesenchymal stem cell therapies for the treatment of knee cartilage damage and osteoarthritis. Cell-based therapy has become a key priority of tissue engineering research focused on functional replacement of cartilage and meniscus regeneration.

A year long animal study has provided research that demonstrates that stem cell treatments provide structural regeneration with mechanical properties comparable with the native cartilage.

The rest is here:
Stem Cell Therapy for Knees - thriveMD Denver & Vail, CO

rn","memberOrganisations":[{"asset_name":"Parenting Research Centre","asset_redirect_url":"https://parentingrc.org.au","asset_metadata_page_content_svg_thumbnail^as_asset:asset_url":"https://raisingchildren.net.au/__data/assets/file/0017/23264/PRC_Stacked_MasterLogo_RGB.svg","asset_url":"https://parentingrc.org.au","asset_thumbnail_url":"https://raisingchildren.net.au/__data/assets/file/0017/23264/PRC_Stacked_MasterLogo_RGB.svg"},{"asset_name":"The Royal Children's Hospital Melbourne","asset_redirect_url":"https://www.rch.org.au","asset_metadata_page_content_svg_thumbnail^as_asset:asset_url":"https://raisingchildren.net.au/__data/assets/file/0016/23263/logo-chm.svg","asset_url":"https://www.rch.org.au","asset_thumbnail_url":"https://raisingchildren.net.au/__data/assets/file/0016/23263/logo-chm.svg"},{"asset_name":"Murdoch Children's Research Institute","asset_redirect_url":"https://www.mcri.edu.au/","asset_metadata_page_content_svg_thumbnail^as_asset:asset_url":"https://raisingchildren.net.au/__data/assets/file/0018/23265/logo-mcri.svg","asset_url":"https://www.mcri.edu.au/","asset_thumbnail_url":"https://raisingchildren.net.au/__data/assets/file/0018/23265/logo-mcri.svg"}]},"footerMenuBlocks":["a23224","a23232","a23240"]}; sq.ready( function() { return sq.siteTree }, function () { sq.globalFooter('global-footer', Object.assign({}, sq.state.site, {lineage: sq.state.page.lineage}, sq.state.footer, { siteTree: sq.siteTree, view: 'GlobalFooterInner' })); } ) })(sq);

Original post:
Stem cell therapy and autism | Raising Children Network

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the Company) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the Company will present both an oral and poster at the European Society of Gene and Cell Therapys (ESGCT) 29th Congress, to be held in Edinburgh from October 11-14, 2022.

Arianna Moiani, Ph.D., Senior Scientist & Team Leader Innovation Gene Therapy, will give an oral presentation on encouraging pre-clinical data that leverages TALEN gene editing technology to develop a hematopoietic stem and progenitor cell (HSPCs)-based gene therapy to treat sickle cell disease.

Eduardo Seclen, Ph.D., Senior Scientist & Team Leader, Gene Editing, will present a poster illustrating a TALEN-based gene editing approach that reprograms HSPCs to secrete alpha-L-iduronidase (IDUA), a therapeutic enzyme missing in Mucopolysaccharidosis type I (MPS-I).

The pre-clinical data presented at ESGCT further demonstrate our ability to leverage TALEN gene editing technology to potentially address genetic diseases, namely, sickle cell disease and lysosomal storage diseases. By correcting a faulty mutation or inserting a corrected gene at the HSPC level, we aim to provide a lifelong supply of healthy cells in a single intervention, said Philippe Duchateau, Ph.D., Chief Scientific Officer at Cellectis. These new milestones bring us one step closer to our goal: providing a cure to patients that have failed to respond to standard therapy.

Presentation details

Pre-clinical data presentation on a non-viral DNA delivery associated with TALEN gene editing that leads to highly efficient correction of sickle cell mutation in long-term repopulating hematopoietic stem cells

Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Cellectis leveraged its TALEN technology to develop a gene editing process that leads to highly efficient HBB gene correction via homology directed repair, while mitigating potential risks associated to HBB gene knock-out.

Overall, these results show that non-viral DNA delivery associated with TALEN gene editing reduces the toxicity usually observed with viral DNA delivery and allows high levels of HBB gene correction in long-term repopulating hematopoietic stem cells.

The oral presentation titled Non-viral DNA delivery associated to TALEN gene editing leads to highly efficient correction of sickle cell mutation in long-term repopulating hematopoietic stem cells, will be made on Thursday, October 13th, 8:30AM-10:45AM BST by Arianna Moiani, Ph.D., Senior Scientist & Team Leader Innovation Gene Therapy. The presentation can be found on the Cellectis website on the day of the presentation.

Presentation details

Pre-clinical data presentation on TALEN-mediated engineering of HSPC that enables systemic delivery of IDUA

Mucopolysaccharidosis type I (MPS-I) is caused by deficiencies in the alpha-L-iduronidase (IDUA) gene and it is associated with severe morbidity representing a significant unmet medical need.

Cellectis established a TALEN-based ex vivo gene editing protocol to insert an IDUA-expression cassette into a specific locus of HSPC.

Editing rates in vivo were 6-9% sixteen weeks after injection, depending on the tissue analyzed (blood, spleen, bone marrow). Lastly, 8.3% of human cells were edited in the brain compartment.

Cellectis established a safe TALEN-based gene editing protocol procuring IDUA-edited HSPCs able to engraft, differentiate into multiple lineages and reach multiple tissues, including the brain.

The poster presentation titled TALEN-mediated engineering of HSPC enables systemic delivery of IDUA, will be made on Thursday, October 13th, 5:30PM - 7:15PM BST by Eduardo Seclen, Ph.D., Senior Scientist & Team Leader, Gene Editing, and can be found on Cellectis website.

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit http://www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:

Pascalyne Wilson,Director,Communications,+33 (0)7 76 99 14 33, media@cellectis.com

Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact:

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617430 7577

Forward-looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as anticipate, believe, intend, expect, plan, scheduled, could, may and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of our preclinical programs and product candidates. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachment

See more here:
Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with ... - The Bakersfield Californian

ReportLinker

Abstract: Whats New for 2022?? Global competitiveness and key competitor percentage market shares. Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW

Online interactive peer-to-peer collaborative bespoke updates

Access to our digital archives and MarketGlass Research Platform

Complimentary updates for one yearGlobal Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027- In the changed post COVID-19 business landscape, the global market for Nerve Repair and Regeneration Devices estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$12.9 Billion by 2027, growing at aCAGR of 10% over the period 2020-2027. Neurostimulation & Neuromodulation Devices, one of the segments analyzed in the report, is projected to record 9.7% CAGR and reach US$10.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biomaterials segment is readjusted to a revised 11.7% CAGR for the next 7-year period.- The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 13% CAGR- The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 13% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 8.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Select Competitors (Total 61 Featured)Abbott Laboratories, Inc.AxoGen, Inc.Boston Scientific CorporationIntegra LifeSciences CorporationLivaNova, PLCMedtronic plcNeuroPace, Inc.Nevro Corporation.Orthomed S.A.S.Polyganics B.V.Stryker CorporationSynapse Biomedical Inc.Synovis Micro Companies Alliance, Inc.

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY1. GLOBAL MARKET OVERVIEWImpact of Covid-19 and a Looming Global Recession2020 Marked as a Year of Disruption & TransformationWorld Economic Growth Projections (Real GDP, Annual % Change)for 2019 to 2022Global Nerve Repair & Regeneration Market Buckles under COVID-19 StrainCovid-19 Patients in Prone Position Suffering Nerve DamageBodes Well for Market GrowthNerve Repair and Regeneration Market Set for a Robust GrowthNeurostimulation & Neuromodulation Devices Hold Commanding Slotin Nerve Repair & Regeneration MarketBiomaterials to Exhibit Rapid GrowthNerve Repair and Regeneration Market by ApplicationUS and Europe Dominate the MarketAsia-Pacific and other Emerging Regions Display ImpressiveGrowth PotentialRecent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERSHigh Incidence of Neurological Disorders: A Key Market DriverAnnual Incidence of Adult-Onset Neurologic Disorders in the USEffects of COVID-19 on the Nervous System Sheds Focus onNeuromodulation ApplicationsIncreasing Cases of Peripheral Nerve Injuries Drive the NerveRepair and Regeneration MarketGrowing Number of Vehicular Accidents Drive the PeripheralNerve injuries Repair MarketRising Geriatric Population and Subsequent Growth in PrevalenceOf Neurological DisordersGlobal Population Statistics for the 65+ Age Group in Millionby Geographic Region for the Years 2019, 2025, 2035 and 2050Growing Incidence of Neurodegenerative Diseases Propels theMarket for Deep Brain Stimulation DevicesGlobal Alzheimers Prevalence by Age GroupDiagnosed Prevalence Cases of Parkinson?s Disease Across SelectCountriesGlobal DBS Market by Leading Player (2020E): Market ShareBreakdown of Revenues for Medtronic, Boston Scientific, andAbbottSelect Available Deep Brain Stimulation Devices Available inthe MarketIntensified Research Activity Across Various Neural DisciplinesInduces Additional OptimismStem Cell Therapy: A Promising Avenue for Nerve Repair andRegenerationIncreasing Cases of Epilepsy Drives the Demand for Vagus NerveStimulation DevicesEpilepsy Incidence by Type (2019): Percentage Share Breakdownfor Idiopathic and Symptomatic EpilepsySymptomatic Epilepsy Incidence by Type (2019): Percentage ShareBreakdown of Congenital, Degenerative, Infective, Neoplastic,Trauma, and Vascular EpilepsySpinal Cord Injuries Propel the Demand for Spinal CordStimulation DevicesRecent Developments in Spinal Cord Injury TreatmentBiomaterials (Nerve Conduits and Nerve Wraps) to Witness RapidGrowthNew Biomaterials Pave the Way for Innovative NeurodegenerationTherapiesRole of Nerve Conduits in the Treatment of Peripheral Nerve InjuryInnovative Nerve Conduits from StrykerTENS (Transcutaneous electrical nerve stimulation devices)Market Witnesses Rapid GrowthNon-Invasiveness of TMS (Transcranial Magnetic Stimulation)Propelling the adoption of TMS devicesNerve Grafts for Bridging Larger Nerve GapsRole of Nerve Grafting in Treatment of Peripheral Nerve InjuriesFDA-approved Nerve Tubes for Peripheral Nerve Repair

4. GLOBAL MARKET PERSPECTIVETable 1: World Recent Past, Current & Future Analysis for NerveRepair and Regeneration Devices by Geographic Region - USA,Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Nerve Repair andRegeneration Devices by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Nerve Repair andRegeneration Devices by Geographic Region - PercentageBreakdown of Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets forYears 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis forNeurostimulation & Neuromodulation Devices by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027and % CAGR

Table 5: World Historic Review for Neurostimulation &Neuromodulation Devices by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Neurostimulation &Neuromodulation Devices by Geographic Region - PercentageBreakdown of Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa for Years2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis forBiomaterials by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Biomaterials by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019and % CAGR

Table 9: World 15-Year Perspective for Biomaterials byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis forNeurostimulation & Neuromodulation Surgeries by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027and % CAGR

Table 11: World Historic Review for Neurostimulation &Neuromodulation Surgeries by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Neurostimulation &Neuromodulation Surgeries by Geographic Region - PercentageBreakdown of Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa for Years2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis forNeurorrhaphy by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Neurorrhaphy by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019and % CAGR

Table 15: World 15-Year Perspective for Neurorrhaphy byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis forNerve Grafting by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Nerve Grafting byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Nerve Grafting byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for StemCell Therapy by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Stem Cell Therapy byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Stem Cell Therapy byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis forHospitals & Clinics by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals & Clinics byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospitals & Clinics byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis forAmbulatory Surgery Centers by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Ambulatory Surgery Centersby Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Ambulatory SurgeryCenters by Geographic Region - Percentage Breakdown of ValueSales for USA, Canada, Japan, China, Europe, Asia-Pacific,Latin America, Middle East and Africa for Years 2012, 2021 &2027Impact of Covid-19 and a Looming Global Recession

III. MARKET ANALYSIS

UNITED STATESNerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Statesfor 2022 (E)Table 28: USA Recent Past, Current & Future Analysis for NerveRepair and Regeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 29: USA Historic Review for Nerve Repair and RegenerationDevices by Product - Neurostimulation & Neuromodulation Devicesand Biomaterials Markets - Independent Analysis of Annual Salesin US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 31: USA Recent Past, Current & Future Analysis for NerveRepair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 32: USA Historic Review for Nerve Repair and RegenerationDevices by Application - Neurostimulation & NeuromodulationSurgeries, Neurorrhaphy, Nerve Grafting and Stem Cell TherapyMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 34: USA Recent Past, Current & Future Analysis for NerveRepair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 35: USA Historic Review for Nerve Repair and RegenerationDevices by End-Use - Hospitals & Clinics and Ambulatory SurgeryCenters Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

CANADATable 37: Canada Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 39: Canada 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 40: Canada Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 41: Canada Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 43: Canada Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 44: Canada Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 45: Canada 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

JAPANNerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)Table 46: Japan Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 48: Japan 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 49: Japan Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 50: Japan Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 52: Japan Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 53: Japan Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 54: Japan 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

CHINANerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)Table 55: China Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 56: China Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 57: China 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 58: China Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 59: China Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 61: China Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 62: China Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 63: China 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

EUROPENerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)Table 64: Europe Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Geographic Region -France, Germany, Italy, UK, Spain, Russia and Rest of EuropeMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Nerve Repair andRegeneration Devices by Geographic Region - France, Germany,Italy, UK, Spain, Russia and Rest of Europe Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Nerve Repair andRegeneration Devices by Geographic Region - PercentageBreakdown of Value Sales for France, Germany, Italy, UK, Spain,Russia and Rest of Europe Markets for Years 2012, 2021 & 2027

Table 67: Europe Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 69: Europe 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 70: Europe Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 71: Europe Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 73: Europe Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 74: Europe Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 75: Europe 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

FRANCENerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)Table 76: France Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 77: France Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 78: France 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 79: France Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 80: France Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 82: France Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 83: France Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 84: France 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

GERMANYNerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022:(E)Table 85: Germany Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 87: Germany 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

See more here:
Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - Yahoo Finance

Citeline shares insights on a longer-term outlook at some key late-stage drugs projected to hit the market in 2023

Citeline(formerly Informa Pharma Intelligence) has recently published the Key Potential Drug Launches in 2023 report sharing insights on a longer-term outlook of some key late-stage drugs projected to hit the market in 2023.

Chronic Heart Failure (CHF) remains a key area of attention for drug makers. In this scenario, Furoscix is a reformulation of the diuretic furosemide which has been developed for the treatment of decompensated heart failure and designed to be self-administered in the outpatient setting through a subcutaneous infusion via a wearable, on-body drug delivery system. Currently, the Prescription Drug User Fee Act (PDUFA) date for Furoscix is set at October 8 2022 following a resubmission of an NDA in April 2022 which included data from the Phase III FREEDOM HF trial, where the overall and heart failure-related costs of treating congestion in patients with CHF were investigated.

Simultaneously, Omecamtiv Mecarbil is another soon-to-be-launched drug, which will provide additional means of improving outcomes on top of the standard of care for those patients with more advanced stages of CHF.

In the Oncology space, for Bone Marrow Transplant and Stem Cell Transplant, Gamida Cells omidubicel is a nicotinamide (NAM)-enabled stem cell therapy being studied for use in allogeneic hematopoietic (bone marrow) stem cell transplants for patients with hematologic malignancies like acute lymphocytic leukemia.

In June 2022, Gamida Cell completed its submission to the FDA for omidubicels biologics license application, with a final decision expected in June 2023 if there are no delays.

Breyanzi has demonstrated encouraging results in the Phase I/II TRANSCEND-CLL-004 trial, reporting higher observed overall response rates compared to other investigational CD 19-directed CAR-T therapies, such as Kymriah. Breyanzi looks set to emerge as a revolutionary option for this last-line treatment setting, pending its supplemental approval in 2023.

For Haematology, Vertex had announced that global regulatory filings for exa-cel (CTX001) in transfusion-dependent beta-thalassemia (TDT) and sickle cell disease are expected by the end of 2022 which if successful, could in 2023 make it the first CRISPR/Cas 9 based product ever approved, an important boost for the gene editing technology.

Go here to read the rest:
2023 to be highly lucrative for drug developers across therapeutic areas: Report - BSI bureau